Not Signed In -
Felbamate Oral Suspension |
Felbatol Oral Suspension |
Clinical Trial: Clinical Trial for Prostate Cancer
This study is no longer recruiting patients.
|
Purpose
Phase III trial using an injectable for treatment of prostate cancer.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Prostate Cancer | Drug: Leuprolide Acetate for Injectable Suspension 22.5 mg | Phase III |
MedlinePlus related topics: Prostate Cancer
Study Type: Interventional
Study Design: Treatment, Open Label, Safety/Efficacy Study
Further Study Details:
Study start: March 2004
Eligibility
Ages Eligible for Study: 40 Years and above, Genders Eligible for Study: Male
Location Information
Study chairs or principal investigators
James A. Page, M.D., Study Chair, Oakwood Laboratories, LLC
More Information
Oakwood (sponsor) site
Study ID Numbers: OL-007
Record last reviewed: September 2004
Last Updated: October 13, 2004
Record first received: January 26, 2004
ClinicalTrials.gov Identifier: NCT00076531
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: September 2004
Last Updated: October 13, 2004
Record first received: January 26, 2004
ClinicalTrials.gov Identifier: NCT00076531
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
Resources
- Felbamate Oral Suspension (Drug Digest)
- Felbatol Oral Suspension (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
